TG Therapeutics’ ublituximab tops Sanofi’s Aubagio in MS trial
Ublituximab significantly reduced the annualised relapse rate in patients with relapsing forms of multiple sclerosis
Read More
Tag: TG Therapeutics
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
